ClinicalTrials.gg
CompletedNCT04259086Updated Jun 27, 2023Results posted

Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines

A Phase 2 interventional study of DaxibotulinumtoxinA for injection in Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines), sponsored by Revance Therapeutics, Inc.. Completed at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-27.

Sponsored by Revance Therapeutics, Inc. (part of Revance) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of DaxibotulinumtoxinA for injection (DAXI for injection) in the treatment of Glabellar Lines (GL), Dynamic Forehead Lines (FHL), and Lateral Canthal Lines(LCL)

02

Conditions studied

  • Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)

Keywords

  • Lateral Canthal Wrinkle
  • crow's feet lines
  • LCL
  • Forehead Lines
  • Glabellar Lines
  • Frown Lines
  • Upper facial lines
03

In context

Lead sponsor

Revance Therapeutics, Inc. is the lead sponsor of 29 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

First submitted before Revance Therapeutics, Inc. became part of Revance.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written consistent with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) guidelines and local laws, including authorization to release health information, signed prior to any study procedures being performed
  2. Be outpatient, male or female subjects, in good general health, 18 years of age or older
  3. Have a score of moderate (2) or severe (3) Glabellar Lines during maximum contraction as assessed by the Investigator Global Assessment-Frown Wrinkle Severity (IGA-FWS) and Patient Frown Wrinkle Severity (PFWS)
  4. Have a score of moderate (2) or severe (3) Forehead Lines during maximum contraction as assessed by the Investigator Global Assessment Forehead Wrinkle Severity (IGA-FHWS) and Patient Forehead Wrinkle Severity (PFHWS)
  5. Have a score of moderate (2) or severe (3) Lateral Canthal Lines at maximum contraction as assessed by the Investigator Global Assessment of Lateral Canthal Wrinkle Severity (IGA-LCWS) and Patient Lateral Canthal Wrinkle Severity (PLCWS) (scores must be consistent bilaterally for each scale considered separately)
  6. Able to understand the requirements of the study and be willing and able to follow all study procedures, attend all scheduled visits, comprehend and complete the questionnaires without outside assistance and successfully complete the study

Exclusion criteria

Exclusion Criteria:

  1. Active skin disease, infections, or inflammation at the injection sites
  2. Planned or anticipated need for surgery or hospitalization through the end of the study
  3. Pregnant, nursing, or planning a pregnancy during the study; or is a Women of Child Bearing Potential () but is not willing to use an effective method of
  4. Current enrollment in an drug or device study or participation in such a study within the last 30 days prior to screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    DAXI 40 U GL / 32 U FHL / 48 U LCL

    DaxibotulinumtoxinA for injection for the treatment of moderate to severe Glabellar Lines (GL), Forehead Lines (FHL), \& Lateral Canthal Lines (LCL)

    Drug: DaxibotulinumtoxinA for injection

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With None or Mild in GL Severity at Maximum Frown

    The percentage of subjects achieving a score of 0 (none) or 1 (mild) in GL severity at maximum contraction (maximum frown) at Week 4 as assessed by the IGA-FWS

    Time frame: Week 4

  2. Percentage of Participants With None or Mild in FHL Severity at Maximum Eyebrow Elevation

    The percentage of subjects achieving a score of 0 (none) or 1 (mild) in FHL severity at maximum contraction (maximum eyebrow elevation) at Week 4 as assessed by the IGA-FHWS

    Time frame: Week 4

  3. Percentage of Participants With None or Mild in LCL Severity at Maximum Smile Effort

    The percentage of subjects achieving a score of 0 (none) or 1 (mild) in LCL severity at maximum contraction (maximum smile effort) at Week 4 as assessed by the IGA-LCWS

    Time frame: Week 4

07

Results

Posted Jun 27, 2023

Participant flow

Participant flow — Overall Study
MilestoneDAXI 40 U GL / 32 U FHL / 48 U LCL
Started48
Completed45
Not completed3

Outcome measures

PrimaryPercentage of Participants With None or Mild in GL Severity at Maximum Frown

The percentage of subjects achieving a score of 0 (none) or 1 (mild) in GL severity at maximum contraction (maximum frown) at Week 4 as assessed by the IGA-FWS

Time frame:
Week 4
Reported as:
Count of participants · Participants
Percentage of Participants With None or Mild in GL Severity at Maximum Frown
ParticipantsDAXI 40 U GL / 32 U FHL / 48 U LCL
Percentage of Participants With None or Mild in GL Severity at Maximum Frown46
PrimaryPercentage of Participants With None or Mild in FHL Severity at Maximum Eyebrow Elevation

The percentage of subjects achieving a score of 0 (none) or 1 (mild) in FHL severity at maximum contraction (maximum eyebrow elevation) at Week 4 as assessed by the IGA-FHWS

Time frame:
Week 4
Reported as:
Count of participants · Participants
Percentage of Participants With None or Mild in FHL Severity at Maximum Eyebrow Elevation
ParticipantsDAXI 40 U GL / 32 U FHL / 48 U LCL
Percentage of Participants With None or Mild in FHL Severity at Maximum Eyebrow Elevation46
PrimaryPercentage of Participants With None or Mild in LCL Severity at Maximum Smile Effort

The percentage of subjects achieving a score of 0 (none) or 1 (mild) in LCL severity at maximum contraction (maximum smile effort) at Week 4 as assessed by the IGA-LCWS

Time frame:
Week 4
Reported as:
Count of participants · Participants
Percentage of Participants With None or Mild in LCL Severity at Maximum Smile Effort
ParticipantsDAXI 40 U GL / 32 U FHL / 48 U LCL
Percentage of Participants With None or Mild in LCL Severity at Maximum Smile Effort44

Adverse events

Collected over The adverse events were collected throughout the entire study, up to 36 weeks after treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DAXI 40 U GL / 32 U FHL / 48 U LCL0/48 (0%)1/48 (2.1%)3/48 (6.3%)
Most frequent serious events
Most frequent serious events
EventDAXI 40 U GL / 32 U FHL / 48 U LCL
COVID-19 pneumoniaInfections and infestations1/48
Most frequent other events
Most frequent other events
EventDAXI 40 U GL / 32 U FHL / 48 U LCL
Injection site erythemaGeneral disorders3/48

Baseline characteristics

Safety Population

Age, Continuous
Age, Continuous(years)DAXI 40 U GL / 32 U FHL / 48 U LCL
Mean48.9 (23 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)DAXI 40 U GL / 32 U FHL / 48 U LCL
Female40
Male8
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DAXI 40 U GL / 32 U FHL / 48 U LCL
Race — White44
Race — Black/African American3
Race — Other1
08

Study locations

8 sites
  • Site 1
    Manhattan Beach, California 90266, United States
  • Site 3
    San Diego, California 92121, United States
  • Site 7
    Santa Monica, California 90404, United States
  • Site 5
    Coral Gables, Florida 33146, United States
  • Site 2
    Chestnut Hill, Massachusetts 02467, United States
  • Site 6
    New York, New York 10028, United States
  • Site 4
    Vancouver, British Columbia V5Z 4E1, Canada
  • Site 8
    Toronto, Ontario M5R3N8, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Nov 2020, 10 months.

Results were first posted in Jun 2023, 2 years 7 months after primary completion. A results delay was requested in Feb 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2019
First posted
Feb 6, 2020
StartActual
Dec 6, 2019
Primary completionActual
Nov 2, 2020
CompletionActual
Nov 2, 2020
Results delay requested
Feb 11, 2021
Results first posted
Jun 27, 2023
Last update
Jun 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04259086
Responsible party
Sponsor
First posted
Feb 6, 2020
Start date
Dec 6, 2019
Primary completion
Nov 2, 2020
Completion
Nov 2, 2020
Results posted
Jun 27, 2023
Last update
Jun 27, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion